Comparative Efficacy of Once-Weekly Somatrogon Versus Daily Growth Hormone Therapy in Children With Idiopathic Growth Hormone Deficiency: A Real-World Retrospective Study From Greece

Introduction Short stature is one of the most common reasons for referral to a pediatric endocrinologist, defined as a height of at least two standard deviations (SD) below the mean for age and sex. In this study, we aimed to compare the efficacy of daily versus weekly growth hormone (GH) treatments on the growth of children with idiopathic growth hormone deficiency (IGHD). Methods In this six-month study, participants were matched 1:1 between once-weekly somatrogon and once-daily GH treatment cohorts. A total of 20 children (aged 4-15 years) with IGHD who had never received GH treatment were included. Results Height gain at six months was 4.58 ± 1.18 cm for somatrogon-treated (weekly) subjects and 4.41 ± 0.87 cm for subjects receiving the daily regimen. Changes in height standard deviation score (SDS) by six months were similar in both treatment groups. Both treatments were well tolerated. Conclusion Both daily and weekly GH regimens significantly increased height and height SDS, with similar efficacy and safety profiles, over the six-month period.